Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Yamanashi, Takehiko ^a   Iwata, Masaaki ^a   Kamiya, Naho ^a   Tsunetomi, Kyohei ^a   Kajitani, Naofumi ^a   Wada, Nodoka ^a   Iitsuka, Takahiro ^a   Yamauchi, Takahira ^b   Miura, Akihiko ^a   Pu, Shenghong ^a   Shirayama, Yukihiko ^c   Watanabe, Ken ^d   Duman, Ronald S ^e   Kaneko, Koichi ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^d Watanabe Hospital   (Japan)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; BIOLOGICAL MARKER; CRYOPYRIN; CYTOKINE;

ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; ANXIETY; DEPRESSION; DRUG EFFECT; HIPPOCAMPUS; INFLAMMATION; MALE; MENTAL STRESS; METABOLISM; PHYSIOLOGICAL STRESS; PSYCHOLOGY; RAT;

3-HYDROXYBUTYRIC ACID; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BIOMARKERS; CYTOKINES; DEPRESSION; HIPPOCAMPUS; INFLAMMATION; MALE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RATS; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL;

EID: 85027181129     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-08055-1     Document Type: Article

References (45)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. 5th ed. Text Revision (DSM-5). (American Psychiatric Association, Washington, DC, 2013).
2. Rush, A. J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry 163, 1905-1917, doi:10.1176/ajp.2006.163.11.1905 (2006).
3. Kim, Y. K., Na, K. S., Myint, A. M. & Leonard, B. E. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuropsychopharmacol Biol Psychiatry 64, 277-284, doi:10.1016/j. pnpbp.2015.06.008 (2016).
4. Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 67, 446-457, doi:10.1016/j.biopsych.2009.09.033 (2010).
5. Koo, J. W. & Duman, R. S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 105, 751-756, doi:10.1073/pnas.0708092105 (2008).
6. Koo, J. W., Russo, S. J., Ferguson, D., Nestler, E. J. & Duman, R. S. Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci USA 107, 2669-2674, doi:10.1073/pnas.0910658107 (2010).
7. Koo, J. W. & Duman, R. S. Interleukin-1 receptor null mutant mice show decreased anxiety-like behavior and enhanced fear memory. Neurosci Lett 456, 39-43, doi:10.1016/j.neulet.2009.03.068 (2009).
8. Iwata, M. et al. Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor. Biol Psychiatry 80, 12-22, doi:10.1016/j.biopsych.2015.11.026 (2016).
9. Koo, J. W. & Duman, R. S. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Investig Drugs 10, 664-671 (2009).
10. Jin, C. & Flavell, R. A. Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol 30, 628-631, doi:10.1007/s10875-010-9440-3 (2010).
11. Iwata, M., Ota, K. T. & Duman, R. S. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 31, 105-114, doi:10.1016/j.bbi.2012.12.008 (2013).
12. Wohleb, E. S., Franklin, T., Iwata, M. & Duman, R. S. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci 17, 497-511, doi:10.1038/nrn.2016.69 (2016).
13. Newman, J. C. & Verdin, E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab 25, 42-52, doi:10.1016/j. tem.2013.09.002 (2014).
14. Cotter, D. G., Schugar, R. C. & Crawford, P. A. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 304, H1060-1076, doi:10.1152/ajpheart.00646.2012 (2013).
15. Youm, Y. H. et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21, 263-269, doi:10.1038/nm.3804 (2015).
16. Lim, S. et al. D-β-hydroxybutyrate is protective in mouse models of Huntington's disease. PLoS One 6, e24620, doi:10.1371/journal. pone.0024620 (2011).
17. Tieu, K. et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest 112, 892-901, doi:10.1172/JCI18797 (2003).
18. Zhang, J. et al. 3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer's disease via mitochondria protection mechanism. Biomaterials 34, 7552-7562, doi:10.1016/j.biomaterials.2013.06.043 (2013).
19. Suzuki, M. et al. Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. Jpn J Pharmacol 87, 143-150 (2001).
20. Fu, S. P. et al. BHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-κB activation. Mediators Inflamm 2014, 983401, doi:10.1155/2014/983401 (2014).
21. Goldberg, E. L. et al. β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares. Cell Rep 18, 2077-2087, doi:10.1016/j.celrep.2017.02.004 (2017).
22. Qian, J., Zhu, W., Lu, M., Ni, B. & Yang, J. D-β-hydroxybutyrate promotes functional recovery and relieves pain hypersensitivity in mice with spinal cord injury. Br J Pharmacol. doi:10.1111/bph.13788 (2017).
23. Pellerin, L., Bergersen, L. H., Halestrap, A. P. & Pierre, K. Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. J Neurosci Res 79, 55-64, doi:10.1002/jnr.20307 (2005).
24. Banasr, M. & Duman, R. S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 64, 863-870, doi:10.1016/j.biopsych.2008.06.008 (2008).
25. Abelaira, H. M., Réus, G. Z. & Quevedo, J. Animal models as tools to study the pathophysiology of depression. Rev Bras Psiquiatr 35(Suppl 2), S112-120, doi:10.1590/1516-4446-2013-1098 (2013).
26. Hill, M. N., Hellemans, K. G., Verma, P., Gorzalka, B. B. & Weinberg, J. Neurobiology of chronic mild stress: parallels to major depression. Neurosci Biobehav Rev 36, 2085-2117, doi:10.1016/j.neubiorev.2012.07.001 (2012).
27. Yin, X., Guven, N. & Dietis, N. Stress-based animal models of depression: Do we actually know what we are doing? Brain Res. doi:10.1016/j.brainres.2016.09.027 (2016).
28. Bogdanova, O. V., Kanekar, S., D'Anci, K. E. & Renshaw, P. F. Factors influencing behavior in the forced swim test. Physiol Behav 118, 227-239, doi:10.1016/j.physbeh.2013.05.012 (2013).
29. Duman, R. S. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci 11, 239-255 (2009).
30. Blasco-Serra, A. et al. Depressive-like symptoms in a reserpine-induced model of fibromyalgia in rats. Physiol Behav 151, 456-462, doi:10.1016/j.physbeh.2015.07.033 (2015).
31. Nestler, E. J. & Hyman, S. E. Animal models of neuropsychiatric disorders. Nat Neurosci 13, 1161-1169, doi:10.1038/nn.2647 (2010).
32. Li, N. et al. Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine. Int J Neuropsychopharmacol 14, 1091-1098, doi:10.1017/S1461145710001082 (2011).
33. Murphy, P., Likhodii, S., Nylen, K. & Burnham, W. M. The antidepressant properties of the ketogenic diet. Biol Psychiatry 56, 981-983, doi:10.1016/j.biopsych.2004.09.019 (2004).
34. Sussman, D., Germann, J. & Henkelman, M. Gestational ketogenic diet programs brain structure and susceptibility to depression & anxiety in the adult mouse offspring. Brain Behav 5, e00300, doi:10.1002/brb3.300 (2015).
35. Brand, S. J., Moller, M. & Harvey, B. H. A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. Curr Neuropharmacol 13, 324-368 (2015).
36. Hannestad, J., DellaGioia, N. & Bloch, M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36, 2452-2459, doi:10.1038/npp.2011.132 (2011).
37. Levine, J. et al. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40, 171-176, doi:26615 (1999).
38. Kaushik, D. K., Gupta, M., Kumawat, K. L. & Basu, A. NLRP3 inflammasome: key mediator of neuroinflammation in murine Japanese encephalitis. PLoS One 7, e32270, doi:10.1371/journal.pone.0032270 (2012).
39. Alcocer-Gómez, E. et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun 36, 111-117, doi:10.1016/j.bbi.2013.10.017 (2014).
40. Iosif, R. E. et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 26, 9703-9712, doi:10.1523/JNEUROSCI.2723-06.2006 (2006).
41. Berkenbosch, F., van Oers, J., del Rey, A., Tilders, F. & Besedovsky, H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 238, 524-526 (1987).
42. Turnbull, A. V. & Rivier, C. L. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 79, 1-71 (1999).
43. Maes, M., Bosmans, E., Meltzer, H. Y., Scharpé, S. & Suy, E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 150, 1189-1193, doi:10.1176/ajp.150.8.1189 (1993).
44. Höschl, C. & Hajek, T. Hippocampal damage mediated by corticosteroids-a neuropsychiatric research challenge. Eur Arch Psychiatry Clin Neurosci 251(Suppl 2), II81-88 (2001).
45. Cryan, J. F., Page, M. E. & Lucki, I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 182, 335-344, doi:10.1007/s00213-005-0093-5 (2005).